Bladder Cancer Journal Vol. 7, Issue 4
The Pros and Cons of “Machination of Medicine” in Genitourinary Practice ABSTRACT: The...
Read MoreSelect Page
Posted by Bladder Cancer Journal | Jan 2022
The Pros and Cons of “Machination of Medicine” in Genitourinary Practice ABSTRACT: The...
Read MorePosted by Bladder Cancer Journal | Sep 2021
Muscle-Invasive Bladder Cancer in Patients with Liver Cirrhosis: A Review of Pertinent...
Read MorePosted by Bladder Cancer Journal | Jun 2021
Rationale for Randomized Clinical Trials Investigating the Potential of BCG Vaccination in...
Read MorePosted by Bladder Cancer Journal | Apr 2021
Tumor Subtyping: Making Sense of Heterogeneity with a Goal Toward Treatment ABSTRACT: BACKGROUND:...
Read MorePosted by Bladder Cancer Journal | Dec 2020
Upregulated FGFR3 signaling in NMIBC and MIBC, the diagnosis and management of checkpoint inhibitor side effects in bladder cancer patients, the etiology of treatment delays in patients receiving neoadjuvant chemotherapy for MIBC, and 25-year trends in stage-specific incidence rates for bladder cancer.
Read More